Artificial intelligence-driven drug repurposing and structural biology for SARS-CoV-2
It has been said that COVID-19 is a generational challenge in many ways. But, at the same time, it becomes a catalyst for collective action, innovation, and discovery. Realizing the full potential of artificial intelligence (AI) for structure determination of unknown proteins and drug discovery are...
Main Authors: | Kartikay Prasad, Vijay Kumar |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Current Research in Pharmacology and Drug Discovery |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2590257121000298 |
Similar Items
-
A review of SARS-CoV-2 drug repurposing: databases and machine learning models
by: Marim Elkashlan, et al.
Published: (2023-08-01) -
Repurposing of Four Drugs as Anti-SARS-CoV-2 Agents and Their Interactions with Protein Targets
by: Luis C. Vesga, et al.
Published: (2022-04-01) -
Artificial intelligence approach fighting COVID-19 with repurposing drugs
by: Yi-Yu Ke, et al.
Published: (2020-08-01) -
Computational repurposing of asthma drugs as potential inhibitors of SARS-CoV-2 Mpro
by: A. Hussain, et al.
Published: (2022-04-01) -
Ligand-Based and Structured-Based In Silico Repurposing Approaches to Predict Inhibitors of SARS-CoV-2 Mpro Protein
by: Alfredo Juárez-Saldívar, et al.
Published: (2020-11-01)